If you have certain forms of breast cancer, your doctor might suggest Kadcyla (ado-trastuzumab emtansine) as a treatment option. It’s a prescription drug used to treat HER2-positive (HER2+) breast ...
All of the women in the study had progressed on two or more HER2-targeted therapies, including Herceptin (trastuzumab) and Tykerb (lapatinib). Kadcyla (ado-trastuzumab emtansine; T-DM1) reduced the ...
Kadcyla outperformed Herceptin regarding overall- and invasive disease-free survival in patients with HER2-positive early breast cancer that still had remaining invasive disease after undergoing ...
Roche’s Kadcyla needs some oomph, and the Swiss drugmaker’s new data might just do the trick. The company is teeing up a new filing for its next-generation breast cancer drug, hoping to gin up more ...
The approval is based on data showing Kadcyla cut the risk of disease recurring by half compared to Herceptin in the adjuvant setting for specific patients with HER2-positive early breast cancer The ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Kadcyla may cause heart problems, including those without symptoms (such as reduced heart function) and those with symptoms (such as congestive heart failure). Symptoms may include swelling of the ...
SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today positive long-term follow-up data from the pivotal, Phase III ...
Breast cancer treatment Kadcyla, will remain available to patients after a last-minute deal on its price between NHS England and pharma company Roche. The drug was one of dozens marked for de-listing ...
How do you put a price on life? How would you know where to start? In the case of the independent NHS watchdog, the National Institute for Health and Care Excellence (Nice), there is a points system, ...
HealthDay News — The FDA has approved ado-trastuzumab emtansine (Kadcyla, Genentech), the fourth treatment approved for patients with human epidermal growth factor receptor 2 (HER2)-positive, ...
The battle of wills between Roche and NICE over the breast cancer drug Kadcyla has entered a new phase – and one that could have an impact for the whole UK industry. Yesterday saw Roche mount its ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results